The mission of the Systems and Computational Biology Core (SCB) is to provide technology resources and support services in systems and computational biology for KCI members, and to promote collaborative research in systems-based oncology across all five Programs. To accomplish this mission, SCB activities are focused in the areas of: 1) workflow planning and experimental design of studies in functional genomics, genetic variation, and cancer systems biology;2) analysis and interpretation of gene expression profiling data (e.g., oncogenomic signatures);3) analysis and modeling of genotype profiling data from both population studies of inherited cancer risk factors and from molecular studies of somatic variation in individual tumors;4) pathway and network modeling of high throughput (""""""""omics"""""""") data for biomarker and drug target discovery;and 5) database management and integration of functional genomics and genotype data for clinical translational oncology (e.g., deployment of NCI caBIG? tools). In particular, SCB activities enable the application of molecular profiling and network modeling approaches to clinical studies ranging from the molecular to the population level. The key service lines for the SCB provide an integrated workflow pipeline for all stages of a systems-based project, from pre-project planning and experimental design through post-experiment data analysis and interpretation. Consultation and user training are key components of SCB's approach to lowering the technology barrier for KCI members who wish to incorporate computational analytics and molecular profiling tools into their research projects.
The Systems and Computational Biology Core provides integrative capabilities that support the translation of results from basic research in cancer biology into practical clinical applications for the diagnosis, prognosis and therapy of cancer as a systemic disease.
|Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008|
|Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017|
|Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597|
|Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697|
|Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4|
|Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133|
|Thakur, Manish K; Ruterbusch, Julie J; Schwartz, Ann G et al. (2018) Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data. J Thorac Oncol 13:46-53|
|Desai, Pinkal; Wallace, Robert; Anderson, Matthew L et al. (2018) An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecol Oncol 148:540-546|
|Mitrea, Cristina; Wijesinghe, Priyanga; Dyson, Greg et al. (2018) Integrating 5hmC and gene expression data to infer regulatory mechanisms. Bioinformatics 34:1441-1447|
|Ma, Huiyan; Ursin, Giske; Xu, Xinxin et al. (2018) Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis. Breast Cancer Res 20:5|
Showing the most recent 10 out of 826 publications